The Food and Drug Administration (FDA) is reportedly interested in conducting a study of so-called “gender-affirming” drugs on minors, potentially with participants as young as 13.
According to POLITICO, the
Research Institute for Gender Therapeutics (RIGT) “said the FDA had
provided feedback on its proposal for a late-stage clinical trial
studying the use of estradiol, a form of the hormone estrogen.” RIGT is a
nonprofit that supports “transitioning” minors. ---More...